Aarti Pharmalabs Limited has completed the allotment of 10,457 equity shares to eligible employees under its Performance Stock Option Plan 2023. The allotment was approved by the company's Nomination and Remuneration Committee during their meeting held on February 09, 2026.

Share Allotment Details

The allotted equity shares carry a face value of Rs. 5 each and were issued pursuant to the exercise of stock options by eligible employees under the Aarti Pharma Performance Stock Option Plan 2023 (PSOP 2023). The allotment complies with the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Updated Share Capital Structure

Following this allotment, Aarti Pharmalabs Limited's paid-up equity share capital has increased significantly. The company's updated capital structure reflects the addition of these employee stock option shares to the existing share base.

The newly allotted equity shares rank pari-passu in all respects with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders.

Regulatory Compliance

The share allotment was conducted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited (Scrip Code: 543748) and National Stock Exchange of India Limited (Symbol: AARTIPHARM) about this corporate action.

The allotment represents the company's commitment to its employee incentive programs and aligns with regulatory requirements for share-based employee benefits. Company Secretary and Legal Head Jeevan Mondkar signed the regulatory filing, confirming the completion of all necessary procedures for the share allotment process.

Aarti Pharmalabs Limited has disclosed receiving a penalty of Rs 2.60 lakhs from the CGST and Central Excise authority, as mandated under Regulation 30 of SEBI Listing Regulations. The penalty was imposed by the Office of the Assistant Commissioner, CGST and Central Excise, Circle-VIII, Vapi, Gujarat, with the order received on February 3rd, 2026.

Penalty Details and Regulatory Action

The penalty has been imposed under Section 74 of the CGST Act, 2017, forming part of a larger alleged demand totaling Rs 31,15,608. This demand amount is inclusive of tax, interest, and penalty components related to GST compliance issues.

Nature of Alleged Violations

The regulatory action stems from alleged discrepancies in the company's GST compliance for financial years 2022-23 and 2023-24. The specific violations identified by the authority include:

• Alleged excess availment of Input Tax Credit
• Incorrect declaration of tax liability
• Discrepancies in data submitted under various GST returns including GSTR-3B, GSTR-1, GSTR-9, and GSTR-2A
• Issues identified in other related records

Financial and Operational Impact

The company has assessed that this penalty will not have any material impact on its financial position, operations, or other business activities. This disclosure suggests that the penalty amount, while significant in absolute terms, is manageable within the company's current financial framework.

Compliance and Next Steps

Aarti Pharmalabs Limited has committed to submitting necessary information and documents to the relevant authority as part of the compliance process. The company has fulfilled its disclosure obligations by informing both BSE and NSE about this development, and has also uploaded the information on its official website at www.aartipharmalabs.com .

The disclosure was signed by Jeevan Mondkar, Company Secretary and Legal Head, ensuring proper corporate governance protocols were followed in communicating this regulatory development to stakeholders.